Hill MP - Search Results

1

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.

Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Di Marzo V, et al. Among authors: hill mp. FASEB J. 2000 Jul;14(10):1432-8. doi: 10.1096/fj.14.10.1432. FASEB J. 2000. PMID: 10877836

2

A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.

van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, Brotchie JM. van der Stelt M, et al. FASEB J. 2005 Jul;19(9):1140-2. doi: 10.1096/fj.04-3010fje. Epub 2005 May 13. FASEB J. 2005. PMID: 15894565

3

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.

Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Hill MP, et al. Mov Disord. 2003 Nov;18(11):1301-5. doi: 10.1002/mds.10542. Mov Disord. 2003. PMID: 14639671

4

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.

Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ. Hill MP, et al. Mov Disord. 2006 Dec;21(12):2090-5. doi: 10.1002/mds.21106. Mov Disord. 2006. PMID: 16991143

5

Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.

Kobylecki C, Hill MP, Crossman AR, Ravenscroft P. Kobylecki C, et al. Among authors: hill mp. Mov Disord. 2011 Nov;26(13):2354-63. doi: 10.1002/mds.23867. Epub 2011 Sep 23. Mov Disord. 2011. PMID: 21953539

6

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Fox SH, et al. Mov Disord. 2002 Nov;17(6):1180-7. doi: 10.1002/mds.10289. Mov Disord. 2002. PMID: 12465055

7

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.

Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Sieradzan KA, et al. Neurology. 2001 Dec 11;57(11):2108-11. doi: 10.1212/wnl.57.11.2108. Neurology. 2001. PMID: 11739835 Clinical Trial.

8

Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes.

East SJ, Hill MP, Brotchie JM. East SJ, et al. Among authors: hill mp. Eur J Pharmacol. 1995 Apr 13;277(1):117-21. doi: 10.1016/0014-2999(95)00119-6. Eur J Pharmacol. 1995. PMID: 7635167

9

Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum.

Hill MP, Brotchie JM. Hill MP, et al. Eur J Pharmacol. 1995 Jul 25;281(1):R1-R2. doi: 10.1016/0014-2999(95)00385-x. Eur J Pharmacol. 1995. PMID: 8566106

10

Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.

Hughes NR, McKnight AT, Woodruff GN, Hill MP, Crossman AR, Brotchie JM. Hughes NR, et al. Among authors: hill mp. Mov Disord. 1998 Mar;13(2):228-33. doi: 10.1002/mds.870130206. Mov Disord. 1998. PMID: 9539334

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

122 results

Search Page

Filters